Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
McKesson
Express Scripts
Federal Trade Commission
Dow
Moodys
Chinese Patent Office
Teva
Harvard Business School

Generated: January 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,655,636

« Back to Dashboard

Which drugs does patent 7,655,636 protect, and when does it expire?

Patent 7,655,636 protects LEXISCAN and is included in one NDA.

This patent has twelve patent family members in twelve countries.
Summary for Patent: 7,655,636
Title:Use of A2A adenosine receptor agonists
Abstract:The present invention relates to methods for producing coronary vasodilation with little peripheral vasodilation by administering doses of a pharmaceutical composition including regadenoson, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, -- an adenosine A.sub.2A receptor agonist -- to a human in an amount sufficient to increase the average coronary peak flow velocity by at least about 16.5 cm/sec.
Inventor(s): Gordi; Toufigh (Sunnyvale, CA), Olmsted; Ann Walls (Palo Alto, CA), Lieu; Hsiao Dee (Burlingam, CA), Belardinelli; Luiz (Palo Alto, CA)
Assignee: Gilead Palo Alto, Inc. (Foster City, CA)
Application Number:11/253,322
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,655,636

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,655,636

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,106,029 Use of A.sub.2A adenosine receptor agonists ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,655,636

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2007114908 ➤ Subscribe
Norway 20072540 ➤ Subscribe
Mexico 2007004749 ➤ Subscribe
South Korea 20070083714 ➤ Subscribe
Japan 2008517063 ➤ Subscribe
Israel 182645 ➤ Subscribe
European Patent Office 1802317 ➤ Subscribe
China 101076343 ➤ Subscribe
Canada 2583185 ➤ Subscribe
Australia 2005295437 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
UBS
Cipla
Healthtrust
Chubb
Citi
Novartis
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot